Abstract |
Many patients with gouty arthritis experience frequent flares and have comorbidities that may limit their anti-inflammatory treatment options for acute flare management. For patients with contraindications to both NSAIDs and/or colchicine, treatment options are particularly limited, and there is an unmet medical need in this subgroup of patients. Two phase 3 studies and their extensions have demonstrated that a single dose of canakinumab during an acute flare provided rapid and effective pain relief and prolonged suppression of flares and inflammation in patients with a history of frequent flares and contraindicated for, intolerant of, or unresponsive to NSAIDs and/or colchicine. Canakinumab was consistently superior to the active comparator triamcinolone acetonide and was generally well tolerated in this patient population with a high prevalence of multiple medical comorbidities. Canakinumab should therefore be considered as a treatment option in a target population of patients with frequent gouty arthritis attacks who are unable to use NSAIDs and colchicine and in whom frequent use of corticosteroids is not considered appropriate.
|
Authors | Thomas Bardin |
Journal | Joint bone spine
(Joint Bone Spine)
Vol. 82 Suppl 1
Pg. eS9-16
(Oct 2015)
ISSN: 1778-7254 [Electronic] France |
PMID | 26717801
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Glucocorticoids
- Gout Suppressants
- Interleukin-1beta
- canakinumab
- Colchicine
|
Topics |
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Arthritis, Gouty
(drug therapy, immunology)
- Colchicine
(therapeutic use)
- Glucocorticoids
(therapeutic use)
- Gout Suppressants
(therapeutic use)
- Humans
- Interleukin-1beta
(antagonists & inhibitors)
|